HOME SITE MAP SEARCH
About Us News Distributors Venofer Injectafer Contract Manufacturing Grant Requests and Investigator Sponsored Trials Jobs Contact Us
PRODUCT CATALOG
All Products
Therapeutic Injectable, Electrolytes & IV Additives
Multiple Trace Element Additives
Multiple Electrolyte Additives
Single Entity Trace Elements
Inhalation & Oral Solutions
Ophthalmics & Otics
Diuretics
Products with vial closures that are not made with natural rubber latex
Preservative Free Products
Product Search
Product Availability
Return Goods Policy
Sales Policy
Vial Closure Information

News & Events

American Regent News, Events and Online Media Kits


Online Media Kit


This information is Intended for Media Professionals

This section has information and resources for journalists, including current fact sheet for Iron Deficiency Anemia and Injectafer® (ferric carboxymaltose injection).

Iron Deficiency Anemia Fact Sheet
Click Here to access the Iron Deficiency Anemia Fact Sheet

Injectafer®  (ferric carboxymaltose injection) Fact Sheet
Click Here to access the Injectafer® Fact Sheet

Full Prescribing Information for Injectafer® (ferric carboxymaltose injection)


Media Inquiries at: ARMediaInquiries@AmericanRegent.com


News

  Caffeine & Sodium Benzoate Injection, USP Important Drug Administration Information
7/18/2016
  IMPORTANT INFORMATION: Drug Supply Chain Security Act (DSCSA)
4/23/2015
  Calcium Chloride Injection, USP 10% Important Drug Administration Information
9/20/2013
  Injectafer® (ferric carboxymaltose injection) receives US FDA approval for the treatment of Iron Deficiency Anemia
7/25/2013
  Calcium Gluconate Injection, USP 10% Important Drug Administration Information
3/18/2013
  Methylergonovine Heathcare Professional Letter
12/18/2012
  American Regent Anounces an FDA Pediatric Indication Exclusivity for Venofer (Iron Sucrose Injection, USP)
10/19/2012
  Betamethasone Healthcare Professional Letter
10/17/2012
  American Regent announces a new FDA-Approved Pediatric Indication for Venofer® (Iron Sucrose Injection, USP)
9/26/2012
  Luitpold Pharmaceuticals Receives Warning Letter from FDA
9/2/2011
  Luitpold Pharmaceuticals Acquires ROXRO PHARMA, Inc., a U.S. Company Developing Acute Pain Products
12/13/2010
  Luitpold Pharmaceuticals, Inc. Acquires PharmaForce, Inc., a U.S. Specialty Injectable Pharmaceutical Company
1/6/2010
  Dexferrum Important Drug Warning and Important Safety Information
9/23/2009
  Luitpold Pharmaceuticals/American Regent Announces Closing of Exclusive Sublicense of Venofer by Fresenius Medical Care in U.S.
9/16/2008
  Venofer Receives FDA Approval for the Treatment of Iron Deficiency Anemia in Peritoneal Dialysis Patients
10/17/2005
1 2
DAIICHI SANKYO NAMES NEW PRESIDENT OF US SUBSIDIARY LUITPOLD PHARMACEUTICALS, INC.

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.